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Synopsis
Summary of Buchbinder R, Ptasznik R, Gordon J,
Buchanan J, Prabaharan V and Forbes A (2002):
Ultrasound-guided extracorporeal shock wave therapy
for plantar fasciitis. A randomised controlled trial.
JAMA 288: 1364-1372. [Prepared by Chris Maher,
Editorial Board member.]
Question: Does ultrasound-guided extracorporeal shock
wave therapy (ESWT) improve, pain function or quality of
life in patients with plantar fasciitis? Design: Randomised
placebo-controlled trial. Setting: Melbourne (Australia)
radiology clinic. Patients: Of 178 patients referred to the
clinic, 169 were eligible for inclusion and 166 consented and
were randomised. Criteria for inclusion included: older than
18 years, presence of plantar heel pain for at least six
weeks and ultrasound confirmed lesion. Exclusion criteria
included: inflammatory arthritis, previous surgery to heel
and previous ESWT to any site. Interventions: Eighty-one
patients were allocated to the active ESWT group and 85 to
placebo ESWT. Both groups received 3-weekly treatments.
In the ESWT group, patients received either 2000 or 2500
shock waves per treatment of energy levels varying
between 0.02 mJ/mm2 and 0.33 mJ/mm2, pulse frequency
gradually increased to 240 per minute, a minimum total
dose of 1000 mJ/mm2 being the treatment goal. In the
placebo group, treatment consisted of 100 shock waves per
treatment, energy level of 0.02 mJ/mm2, frequency 60 per
minute, total dose 6.0 mJ/mm2. Outcomes: Overall,
morning and activity pain were measured with 100 mm
visual analogue scales, reported walking tolerance was
measured on a 6-point ordinal scale, disability was
measured with the Maryland Foot Score (range 0-100) and
a patient-specific measure (the Problem Elicitation
Technique), quality of life was measured with the SF-36
(eight sub-scales each scored 0-100). Outcomes were
assessed at six and 12 weeks by a blinded assessor and
analysed according to the intention-to-treat principle.
Result: There were no clinically significant differences
between groups at baseline. In general, there were no
statistically significant between-group differences for any
outcome (two sub-scales of the SF-36 were marginally
significant at six weeks, p = 0.03 and 0.05, and favoured
placebo). For example, at 12 weeks the between-group
difference (95% CI) for change in overall pain was 0.6 (-
10.3; 11.5), morning pain 0.2 (-12.7; 13.1), Maryland Foot
Score 1.2 (-7.6; 5.3), SF-36 Physical Function score -2.3 (-
9.9; 5.3). Conclusion: In patients with plantar fasciitis,
ESWT is not effective in improving pain, function or quality
of life.
Commentary
A Cochrane review and three systematic reviews have
provided conflicting conclusions on the efficacy of ESWT.
Heller and Niethard’s (1998) meta-analysis of 24 RCTs
(1585 patients) concluded that ESWT was of clinical
benefit.  Bodekker et al (2001) reviewed 21 RCTs specific
to plantar fasciopathy and determined that none of the trials
satisfied all their criteria and that further RCTs were
needed. Crawford et al (2002) concluded that limited
evidence existed supporting the effectiveness of low energy
ESWT. Ogden et al (2002), in a meta-analysis of eight
RCTs (840 patients), concluded that ESWT directed at the
enthesis of the plantarfascia on the inferior calcaneus is a
“safe and effective non-surgical method of treating chronic,
recalcitrant heel pain syndrome that has been refractory to
other commonly used non-operative procedures.”  
There are a number of possible reasons for the Buchbinder
et al result.  Firstly this study included subjects with a
relatively short symptom duration (from eight weeks with
median duration 36 weeks) whereas previous studies have
not included subjects of less than 24 weeks duration, which
may be prior to the processes of the inflammatory response
having stabilised and prior to maturation of scarring within
the fascia. Secondly, the authors describe the ESWT focus
targeting criteria as being within the thickest area of the
plantar fascia. This may differ from results obtained in
studies that have targeted, under imaging guidance, the
symptomatic region at the enthesis and obtained a
treatment effect. 
This study does not support the use of ESWT in subjects
who have a symptom pattern of less than 24 weeks.
Gordon Waddington
The University of Sydney
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